Abstract:The advent of tyrosine kinase inhibitors (TKIs) as treatment of chronic myeloid leukemia (CML) is a paradigm in molecularly targeted cancer therapy. Nonetheless, TKI insensitive leukemia stem cells (LSCs) persist in most patients even after years of treatment. The sustained presence, heterogeneity and evolvability of LSCs are imperative for disease progression as well as recurrence during treatment-free remission (TFR). However, dynamic changes among LSC sub-populations upon TKI therapy impede their measurement and targeting. Here, we used cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) to generate high-resolution single cell multiomics maps from CML patients at diagnosis, retrospectively stratified by BCR::ABL1 (%) following 12 months of TKI therapy as per European LeukemiaNet (ELN) recommendations. Simultaneous measurement of global gene expression profiles together with >40 surface markers from the same cells revealed that each patient harbored a unique composition of stem and progenitor cells at diagnosis demonstrating that cellular heterogeneity is a hallmark of CML. The patients with treatment failure after 12 months of therapy had markedly higher abundance of molecularly defined primitive cells at diagnosis compared to the optimal responders. Furthermore, deconvolution of an independent dataset of CML patient-derived bulk transcriptomes (n=59) into constituent cell populations showed that the proportion of primitive cells versus lineage primed sub-populations significantly connected with the TKI-treatment outcome. The multiomic feature landscape enabled visualization of the primitive fraction as a heterogenous mixture of molecularly distinct Lin CD34 CD38 BCR::ABL1 LSCs and BCR::ABL1 hematopoietic stem cells (HSCs) in variable ratio across patients and guided their prospective isolation by a combination of CD26 and CD35 cell surface markers. We for the first time show that BCR::ABL1 LSCs and BCR::ABL1 HSCs can be distinctly separated as CD26 CD35 and CD26 CD35 respectively. In addition, we found the relative proportion of CD26 CD35 HSCs to be higher in optimal responders when compared to treatment failures, at diagnosis as well as following 3 months of TKI therapy, and that the LSC/HSC ratio was increased in patients with prospective treatment failure. Collectively, the patient-specific cellular heterogeneity multiomics maps build a framework towards understanding therapy response and adapting treatment by devising strategies that either extinguish TKI-insensitive LSCs or engage the immune effectors to suppress the residual leukemogenic cells.

Single Cell Sequencing Reveals Cell Populations That Predict Primary Resistance to Imatinib in Chronic Myeloid Leukemia.

Integrating Single-Cell Transcriptome and Network Analysis to Characterize the Therapeutic Response of Chronic Myeloid Leukemia

Single cell multi-omics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response

Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response

[Transcriptome Analysis of Chronic Myelogenous Leukemia Cell Line with Imatinib Resistance]

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia

Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets

ABCB1 Polymorphisms Predict Imatinib Response in Chronic Myeloid Leukemia Patients: a Systematic Review and Meta-Analysis.

Mutational Landscape of Cfdna Identifies Distinct Molecular Features Associated with Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.

Integrative single-cell analysis of longitudinal t(8;21) AML reveals heterogeneous immune cell infiltration and prognostic signatures

Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line

Targeted single‐cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis‐resistant state in hematologic malignancies

Dynamic Single-Cell RNA-Seq reveals mechanism of Selinexor-Resistance in Chronic myeloid leukemia

Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses

Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia

Targeted Next-Generation Sequencing Identifies Additional Mutations Other than <i>BCR proportion ABL</i> in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study

Subclones of Bone Marrow CD34+ Cells in Acute Myeloid Leukemia at Diagnosis Confer Responses of Patients to Induction Chemotherapy

Quantitative Proteomic Analysis of Plasma Exosomes to Identify the Candidate Biomarker of Imatinib Resistance in Chronic Myeloid Leukemia Patients

Single-cell Transcriptome Analysis Uncovers Heterogeneity and Key Regulators in Ibrutinib-resistant Chronic Lymphocytic Leukemia

Screening and Identification of Key Genes in Imatinib-Resistant Chronic Myelogenous Leukemia Cells: a Bioinformatics Study